• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Affimed N.V. - Common Stock (NQ:AFMD)

    0.1251 -0.0089 (-6.64%)
    Streaming Delayed Price Updated: 3:00 PM EDT, May 14, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 7,643,596
    Open 0.1128
    Bid (Size) 0.1251 (69)
    Ask (Size) 0.1264 (8)
    Prev. Close 0.1340
    Today's Range 0.1010 - 0.1470
    52wk Range 0.1300 - 8.950
    Shares Outstanding 15,227,463
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Wednesday's pre-market session: top gainers and losers
    Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
    Via Chartmill
    Affimed Announces Receipt of Nasdaq Delisting Notice
    From Affimed N.V.
    Via GlobeNewswire

    Performance

    YTD
    -90.7%
    -90.7%
    1 Month
    -84.2%
    -84.2%
    3 Month
    -88.0%
    -88.0%
    6 Month
    -96.7%
    -96.7%
    1 Year
    -97.6%
    -97.6%

    More News

    Read More
    These stocks are moving in today's session
    Via Chartmill
    A Look Ahead: Affimed's Earnings Forecast
    Via Benzinga
    Crude Oil Gains 3%; US Inflation Eases In April
    Via Benzinga
    Topics Economy
    Exposures Fossil Fuels Interest Rates
    Nasdaq Rises Over 1%; Under Armour Posts Strong Q4 Sales
    Via Benzinga
    This Caterpillar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
    Via Benzinga
    Affimed Announces Filing for the Opening of Insolvency Proceedings
    From Affimed N.V.
    Via GlobeNewswire
    This Rapid7 Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday
    Via Benzinga
    Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Receives Nasdaq Deficiency Notice Over Low Share Price: Retail’s In Wait-And-Wait Mode
    Via Stocktwits
    Topics World Trade
    Exposures Tariff
    Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
    From Affimed N.V.
    Via GlobeNewswire
    Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
    From Affimed N.V.
    Via GlobeNewswire
    Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Reports Third Quarter 2024 Financial Results & Business Update
    From Affimed N.V.
    Via GlobeNewswire
    Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
    From Affimed N.V.
    Via GlobeNewswire
    Earnings Scheduled For November 14, 2024
    Via Benzinga

    Frequently Asked Questions

    Is Affimed N.V. - Common Stock publicly traded?
    Yes, Affimed N.V. - Common Stock is publicly traded.
    What exchange does Affimed N.V. - Common Stock trade on?
    Affimed N.V. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Affimed N.V. - Common Stock?
    The ticker symbol for Affimed N.V. - Common Stock is AFMD on the Nasdaq Stock Market
    What is the current price of Affimed N.V. - Common Stock?
    The current price of Affimed N.V. - Common Stock is 0.1251
    When was Affimed N.V. - Common Stock last traded?
    The last trade of Affimed N.V. - Common Stock was at 05/14/25 03:00 PM ET
    What is the market capitalization of Affimed N.V. - Common Stock?
    The market capitalization of Affimed N.V. - Common Stock is 1.90M
    How many shares of Affimed N.V. - Common Stock are outstanding?
    Affimed N.V. - Common Stock has 2M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.